Review
Oncology
Benedetta Maria Motta, Mario Masarone, Pietro Torre, Marcello Persico
Summary: Non-alcoholic fatty liver disease is a common condition affecting a significant portion of the population in developed and developing countries, and it has become a major cause of hepatocellular carcinoma. This review focuses on the epidemiology, risk factors, and management strategies for hepatocellular carcinoma associated with non-alcoholic fatty liver disease.
Review
Gastroenterology & Hepatology
Yuichiro Eguchi, Gabriel Wong, I-Heng Lee, Omar Akhtar, Ricardo Lopes, Yoshio Sumida
Summary: In Japan, hepatocellular carcinoma is the most common malignancy and cause of death among NAFLD/NASH patients, with higher mortality observed among those with advanced disease and complications. Early identification and effective treatments are needed.
HEPATOLOGY RESEARCH
(2021)
Article
Gastroenterology & Hepatology
Adrian T. Billeter, Philip C. Mueller, Thomas Albrecht, Stephanie Roessler, Moritz Loeffler, Anastasia Lemekhova, Arianeb Mehrabi, Beat P. Mueller-Stich, Katrin Hoffmann
Summary: The study found that patients with non-cirrhotic NASH-HCC have comparable oncological outcomes with other underlying etiologies, and despite the lack of cirrhosis, these patients have the same risks of HCC recurrence as patients with cirrhotic liver disease of other etiologies.
JOURNAL OF GASTROINTESTINAL SURGERY
(2021)
Article
Gastroenterology & Hepatology
Grazia Pennisi, Rosaria Maria Pipitone, Daniela Cabibi, Marco Enea, Manuel Romero-Gomez, Mauro Vigano, Elisabetta Bugianesi, Vincent Wai-Sun Wong, Anna Ludovica Fracanzani, Giada Sebastiani, Annalisa Berzigotti, Francesca Di Salvo, Antonino Giulio Giannone, Claudia La Mantia, Giulia Lupo, Rossana Porcasi, Federica Vernuccio, Rossella Zito, Vito Di Marco, Calogero Camma, Antonio Craxi, Victor de Ledinghen, Stefania Grimaudo, Salvatore Petta
Summary: The presence of a cholestatic pattern in patients with NAFLD predicts a higher risk of major liver-related outcomes independently from other features of liver disease.
LIVER INTERNATIONAL
(2022)
Review
Biochemistry & Molecular Biology
Annalisa Cespiati, Felice Cinque, Marica Meroni, Rosa Lombardi, Paola Dongiovanni, Anna Ludovica Fracanzani
Summary: Non-alcoholic fatty liver disease (NAFLD) is a common cause of liver disease worldwide, with potential progression to hepatocellular carcinoma (HCC). The prevalence of NAFLD and consequently HCC is expected to increase in the coming years, posing a significant public health problem. Monitoring HCC in NAFLD patients has limitations, and new biomarkers and scores have been proposed for early diagnosis. This review explores the differences in HCC features between NAFLD and non-NAFLD patients, as well as the limitations of tumor surveillance in NAFLD patients and new biomarkers for early diagnosis.
Article
Gastroenterology & Hepatology
Yueqi Zhang, Yue Luo, Xinhui Liu, Matti Kiupel, Aimin Li, Hongbing Wang, Qing-Sheng Mi, Hua Xiao
Summary: This study reveals a novel mechanism for the onset of NAFLD/NASH and HCC initiated by NCOA5-deficient macrophages, suggesting the NCOA5-PF4 axis in macrophages as a potential target for developing preventive and therapeutic interventions against NAFLD/NASH and HCC.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2024)
Review
Oncology
Anna Kakehashi, Shugo Suzuki, Hideki Wanibuchi
Summary: This review focuses on recent research in the field of non-alcoholic fatty liver disease (NAFLD) or metabolic dysfunction-associated steatotic liver disease (MASLD) and steatohepatitis (NASH)-associated liver cancer. The authors aim to highlight recent omics research on novel genetic and protein contributions to NAFLD/NASH and discuss mainstream molecular pathways and potential biomarkers and molecular targets. Special attention is given to the role of mTOR in the progression from NASH to hepatocellular carcinoma (HCC).
Review
Gastroenterology & Hepatology
Luca Valenti, Federica Pedica, Massimo Colombo
Summary: Hepatocellular carcinoma (HCC) is increasing globally, with nonalcoholic fatty liver disease (NAFLD) being a major contributing factor. NAFLD-related HCC has a higher incidence rate in the Far East, associated with the obesity and diabetes epidemic. NAFLD-HCC is frequently associated with cardiovascular comorbidities, absence of cirrhosis in some patients, and persistently normal transaminase values.
DIGESTIVE AND LIVER DISEASE
(2022)
Review
Biochemistry & Molecular Biology
Paola Dongiovanni, Marica Meroni, Miriam Longo, Silvia Fargion, Anna Ludovica Fracanzani
Summary: Nonalcoholic fatty liver disease (NAFLD) is the main contributor to chronic liver diseases globally, with potential progression from simple steatosis to nonalcoholic steatohepatitis (NASH) and eventually liver cancer. Various factors, including genetic and environmental factors, diet and lifestyle habits, can accelerate the worsening of the disease.
Review
Biochemistry & Molecular Biology
Atsushi Umemura, Seita Kataoka, Keiichiro Okuda, Yuya Seko, Kanji Yamaguchi, Michihisa Moriguchi, Takeshi Okanoue, Yoshito Itoh
Summary: Nonalcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), is a growing cause of liver cirrhosis and liver cancer worldwide. Contrary to the advancements in therapies for viral hepatitis, effective treatments remain unestablished for patients with NAFLD.
Article
Biochemistry & Molecular Biology
Yu Sun, Hadrien Demagny, Kristina Schoonjans
Summary: Liver receptor homolog-1 (LRH-1) plays crucial roles in the liver, not only regulating bile acid and cholesterol homeostasis but also coordinating various other hepatic metabolic processes. Recent advances have highlighted LRH-1 as an attractive target for treating non-alcoholic fatty liver disease and hepatocellular carcinoma.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
(2021)
Article
Gastroenterology & Hepatology
Stephen A. Harrison, Rohit Loomba, Julie Dubourg, Vlad Ratziu, Mazen Noureddin
Summary: Nonalcoholic fatty liver disease is a spectrum of diseases that may progress to nonalcoholic steatohepatitis (NASH) and potentially lead to severe liver conditions. The prevalence of NASH has increased along with the rise in obesity and type 2 diabetes. Efforts have been made to develop effective treatments, with promising results in recent clinical trials.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Review
Geriatrics & Gerontology
Elena S. George, Surbhi Sood, Robin M. Daly, Sze-Yen Tan
Summary: The review explores the association between NAFLD and cognitive function. The results from 11 observational studies suggest that NAFLD is associated with lower cognitive performance across several domains.
Review
Oncology
James A. Thomas, Bradley J. Kendall, Christine Dalais, Graeme A. Macdonald, Aaron P. Thrift
Summary: Non-alcoholic fatty liver disease (NAFLD) is associated with hepatocellular carcinoma (HCC) and extrahepatic cancer. The incidence rate of HCC is higher in patients with advanced liver fibrosis or cirrhosis, while the incidence rate of extrahepatic cancers is even higher. These findings emphasize the importance of prevention and early detection of cancer in adults with NAFLD.
EUROPEAN JOURNAL OF CANCER
(2022)
Review
Oncology
Ju Youn Kim, Feng He, Michael Karin
Summary: NASH and HCC, two liver diseases related to obesity, are influenced by cholesterol and metabolic regulators in their development.